Hypermethylation of normal mucosa of esophagus-specific 1 is associated with an unfavorable prognosis in patients with non-small cell lung cancer

Oncology Letters
Dong Sun KimJae Yong Park

Abstract

Lung cancer is the leading cause of cancer-associated mortality due to high incidence and poor survival rates, irrespective of global variations in its biology and treatment. Changes in DNA methylation are frequent in cancer and constitute an important mechanism in tumorigenesis. Normal mucosa of esophagus-specific 1 (NMES1) is expressed in epithelial tissue and is believed to be a tumor suppressor gene. The present study investigated the methylation status of the NMES1 promoter in 178 cases of primary non-small cell lung cancer (NSCLC) by pyrosequencing and evaluated the prognostic value of this methylation. NMES1 methylation-positive tumors above the background threshold for non-malignant tissue were found in 15 cases (8.4%) and were detected exclusively in malignant tissues. In addition, univariate and multivariate analyses showed that methylation-positive patients experienced worse overall survival rate (OSR) compared with methylation-negative patients (adjusted hazard ratio, 2.62; 95% confidence interval, 1.20-5.69; P=0.02). Notably, within the methylation-positive group, patients with strong methylation tended to experience worse OSR compared with those with weak methylation (adjusted hazard ratio, 2.45 vs. 3.05; Ptrend=0...Continue Reading

References

Sep 5, 2002·International Journal of Cancer. Journal International Du Cancer·Jin ZhouZhihua Liu
Jan 26, 2006·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Pavel SovaNancy Kiviat
Jul 9, 2009·Chest·Frank C DetterbeckLynn T Tanoue
Feb 24, 2010·Cancer Science·Dong Sun KimJae Yong Park
May 18, 2011·Genes & Development·Aimée M Deaton, Adrian Bird
Sep 24, 2011·Nature Reviews. Cancer·Stephen B Baylin, Peter A Jones
May 2, 2012·Cancer Letters·Triantafillos LiloglouMichael P A Davies
May 23, 2012·Genome Research·Suhaida A SelamatIte A Laird-Offringa
Dec 19, 2012·Cancer Cell·Saul A BertSusan J Clark
Jan 9, 2014·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal
Jan 15, 2014·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Letícia da Conceição BragaAgnaldo Lopes da Silva Filho
Mar 4, 2014·Epigenomics·Kimberly WalterDavid S Shames
Oct 16, 2015·Oncotarget·Jose M Garcia-Heredia, Amancio Carnero
Oct 17, 2015·Advances in Clinical Chemistry·Hoseok I, Je-Yoel Cho
Jul 9, 2016·Nature Reviews. Cancer·Ashley J Vargas, Curtis C Harris
Apr 19, 2017·Journal of Surgical Oncology·Amanda McIntyre, Apar Kishor Ganti

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
PCR

Software Mentioned

ImageJ

Related Concepts

Related Feeds

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.